Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Abstract Pevonedistat (TAK924) is a Nedd8-activating enzyme inhibitor with preclinical activity in non-Hodgkin lymphoma (NHL). This open-label, Phase I, multicenter, investigator-sponsored study enrolled patients with relapsed/refractory (R/R) NHL and chronic lymphocytic leukemia (CLL). The primary...

Full description

Bibliographic Details
Main Authors: Pallawi Torka, Swetha Kambhampati Thiruvengadam, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D. Lynne Smith, Alex F. Herrera, Stephen E. F. Spurgeon, Byung Park, Lionel D. Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V. Danilov
Format: Article
Language:English
Published: Nature Publishing Group 2023-01-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00763-w

Internet

https://doi.org/10.1038/s41408-022-00763-w

Similar Items